Lurbinectedin Phase 3 Trial for Relapsed SCLC Completes Primary Study

The primary study for the Phase 3 LAGOON clinical trial, investigating lurbinectedin for relapsed small cell lung cancer (SCLC), was completed on 2026-04-10. This multicenter, open-label, randomized, controlled trial enrolled 705 participants to evaluate lurbinectedin as a single agent or in combination with irinotecan.

Background

The LAGOON trial focused on patients with relapsed small cell lung cancer (SCLC) who had previously failed one line of platinum-containing chemotherapy. This patient population represents a significant unmet medical need, as treatment options are limited after initial platinum-based regimens.

Trial design

The Phase 3 LAGOON study (NCT05153239) is a multicenter, open-label, randomized, controlled clinical trial that enrolled 705 participants with relapsed small cell lung cancer (SCLC). The trial was designed to compare the activity and safety of two experimental arms against an investigator's choice control arm. Group A received lurbinectedin as a single agent, Group B received lurbinectedin in combination with irinotecan, and Group C (control arm) received either topotecan or irinotecan, chosen by the investigator. The study aimed to evaluate these treatments in patients who had previously failed one line of platinum-containing chemotherapy.

What this means

The primary completion of the Phase 3 LAGOON trial signifies that data collection for the primary endpoints has concluded for all 705 participants. This is a crucial milestone in the clinical development of lurbinectedin for relapsed small cell lung cancer. While the primary completion indicates the study has reached a significant stage, specific efficacy and safety results are not yet available. Clinicians and researchers will await the full analysis and publication of these results to understand the potential impact of lurbinectedin, either as a single agent or in combination with irinotecan, compared to standard treatments in this patient population.

Source

The information regarding the primary completion of this trial was obtained from ClinicalTrials.gov, a public database of clinical studies. The update for the study NCT05153239, titled "Clinical Trial of Lurbinectedin as Single-agent or in Combination With Irinotecan Versus Topotecan or Irinotecan in Patients With Relapsed Small-cell Lung Cancer (LAGOON)", was posted on 2026-04-10 on clinicaltrials.gov.